54 results about "Treatment use" patented technology

This invention relates to the use of compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, in the treatment or prevention of mycobacterial infections, wherein: one of R2 and R3 is H, and the other is (CR) a R b ) n Y; Y is selected from CO2R c CN and CONR e R f R4 is selected from H, halogens, CN, alkyl and alkoxy groups; R6 is selected from H, F, Br, I, COOH, CN, COR. d CO2R d Alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, OH, SR d SOR d SO2R d SO2NR d R d NHSO2R d aryl and heteroaryl groups, wherein the aryl or heteroaryl group is optionally substituted by one or more substituents selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkoxy groups; R7 is selected from H, halogen, alkyl, and alkoxy groups; R9 is selected from H, COR... d Alkyl, haloalkyl, aryl, CO-aryl, CO-haloaryl, aralkyl and haloaralkyl; R1, R5 and R8 are H; each R a R b R c R d R e and R f The compounds are independently selected from H, alkyl, and haloalkyl groups; n is 1 to 6. Other aspects of the invention relate to subgroups of compounds of formula (Ia), pharmaceutical compositions comprising such subgroups, and their use in the treatment or prevention of mycobacterial infections.

Methods of treating a condition which is treatable with SSR-125543 or a pharmaceutically acceptable salt thereof in a subject in need thereof are provided. The methods of treatment include predicting a treatment response of a subject to a treatment with SSR-125543 and / or detecting a polymorphism genotype associated with a treatment response of a subject to treatment with SSR-125543. Sets of at least one polymorphism genotype useful in the predicting and / or detecting steps are also disclosed.

The present disclosure concerns genetic modification of fibroblasts or fibroblast-derived materials (including of the fibroblasts from which the fibroblast-derived materials are derived). In specific aspects, they are modified such that they may express one or more surface markers that allow targeting to a tissue and / or organ of interest. In some aspects, they are modified such that they may lose one or more surface markers that then allow targeting to a tissue and / or organ of interest. In certain aspects, one or more surface markers are modified that then allows targeting to a tissue and / or organ of interest.

The invention relates to methods and compositions for preventing or treating a neuropathology in a subject associated with or induced or caused by a P. gingivalis infection, preventing the deposition of or reducing the level of P. gingivalis gingipain in neuronal tissue, delaying the onset of a P. gingivalis-induced or associated neuropathology, for preventing or slowing the rate of abnormal protein deposition in the neuronal tissue, and / or reducing neuroinflammation, the methods comprising administering an RNA polynucleotide encoding a protein comprising or consisting of: - one or more amino acid sequences of an active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and / or - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, wherein the polynucleotide is capable of being translated in a mammalian cell.

Non-natural peptides having the ability to inhibit the A-kinase anchoring function of PI3K gamma, comprising an amino acid sequence as set forth in SEQ ID NO: 1, wherein each amino acid is a D-amino acid, and therapeutic uses and compositions thereof.

The disclosure relates to means and methods in the treatment of a subject having a colorectal cancer. The disclosure in particular relates to therapeutic uses and methods involving a bispecific antibody that binds EGFR and cMET. Such bispecific antibody is particularly useful in the treatment of metastatic colorectal cancer or a locally advanced, unresectable colorectal cancer. The disclosure further relates to uses in such methods and to the use in the manufacture of a medicament for the treatment of such cancers.

The present invention relates to compounds of Formula I, in which Y, Ar1, Ar2, X, R1, and R2 are defined herein, and to their use in various biological imaging techniques and therapeutic methods. The present invention relates, in aspects, to conjugates comprising compounds of Formula I and their related uses and therapeutic uses.

Disclosed herein are compounds of Formula I, and / or stereoisomers, stable isotopes, or pharmaceutically acceptable salts or solvates thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transfection (RET) and potentially useful in the treatment of RET-associated diseases, such as RET-associated cancers.

The present disclosure relates to pharmaceutical compositions comprising a synthetic transcription elongation factor (SynTEF) and an epigenetic inhibitor (e.g., a histone deacetylase (HDAC) inhibitor). As detailed herein, the disclosed compositions and combinations can be used to target FGF14b in Friedreich's ataxia (FRDA / FA), SCA27b, and other GAA-repeat based diseases.

Described herein are compounds that block the activity of LOX family members having good IC50 values, no cellular toxicity below 10 μM, induce sensitization of the cells to doxorubicin, strong activity in a recombinant LOX / LOXL2 activity, and a chemical structure that is drug-like and does not have a PAINS flag, as well as, methods of treatment using the compounds with respect to cancer, organ fibrosis, neurodegenerative and cardiovascular diseases.

Provided are compositions and methods for treating cancers, in particular those characterized with PSMA expression such as prostate cancer. The compositions include a conditionally-activatable XTENylated Protease-Activated bispecific T Cell Engager targeting PSMA (PSMA-XPAT) that remain inactive until activated by proteases present in tumor microenvironment. The PSMA-XPAT exhibited exceptional safety profiles even at high doses and were efficacious in cancer patients resistant to even multiple lines of prior therapies.

In some aspects, the present disclosure pertains to systems that comprise (a) a reactive polymer comprising a plurality of first hydrophilic polymer segments and a plurality of first reactive moieties, (b) a reactive multifunctional compound comprising a plurality of second reactive moieties, and (c) gold nanoparticles that are functionalized with a plurality of second hydrophilic polymer segments. In other aspects, the present disclosure pertains to crosslinked reaction products formed from such systems. In further aspects, the present disclosure pertains to methods of treatment using systems and such crosslinked reaction products.

Disclosed is a system provided with a vibration device and cooling fluid for interstitial laser therapy. Use of the vibration device to vibrate at least part of the system releases and assists in the transfer of gas bubbles (e.g. steam) produced during treatment use, thus stabilising the temperature at or near a treatment site. The system for interstitial laser therapy includes an optical waveguide having an optical output end and an associated optical diffuser, an irrigation tube, an outer tube (e.g. cannula) and a vibration device. The irrigation tube directs cooling fluid to flow out of a distal end of the irrigation tube which directs cooling fluid to flow inside of and / or outside of the optical diffuser. The vibration device is used to vibrate the irrigation tube, the optical diffuser and / or the outer tube.

The present disclosure provides use of a binding agent that binds to EpCAM and CD137 in combination with a PD-1 axis binding antagonist in the treatment or prevention of a tumor or cancer, or in the prevention of progression of a tumor or cancer.

This invention generally relates to the use of hydroxycinnamic acid or its derivatives, such as alginate, in cosmetic or therapeutic settings. The invention further relates to compositions comprising hydroxycinnamic acid or its derivatives.

A treatment system and a treatment procedure are provided that improve the efficiency of an examination or treatment using an endoscope. A treatment system (20) comprises a tubular element (31) having a hollow section (31S) therein and a treatment part (32) at a distal end section (31A), the treatment part being provided on an outer circumference of the hollow section (31S), wherein the tubular element (31) has a proximal end surface (311) on the side of a proximal end section (31B) and a distal end surface (312) on the side of a distal end section (31A) in an axial direction and has a proximal end opening (31A) connected to the hollow section (31S) on at least the proximal end surface (311).

Disclosed are, inter alia, combinations comprising a first antisense (e.g., first double stranded RNAi (dsRNAi)) agent for inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, and a second antisense agent (e.g., second dsRNAi agent) for inhibiting expression of lipoprotein (a) (Lp(a)); pharmaceutical compositions including the same, and methods of treatment using the same.

The disclosure is directed to methods of reducing blood pressure, treating hypertension, improving athletic performance, and increasing aerobic capacity, stamina, muscle strength, endurance, and / or time to exhaustion in a subject comprising co-administering to the subject elemental metal and a source of nitrate anion (NO3) The disclosure is also directed to related compositions comprising elemental metal and a source of nitrate anion (NO3).

The present invention provides pharmaceutical compositions, therapeutic uses, and methods useful for designing and therapeutically using solubilized apirase polypeptides, and for preventing and treating tissue damage. [Solution] A solubilized human apirase is provided having at least two modifications selected from a list consisting of N-terminal deletion, C-terminal deletion, and central modification.

The composition and methods of treatment disclosed or contemplated herein include compositions and methods of treatment for liver-related diseases. The overall treatment strategy would involve the identification of a target protein or receptor within the liver that is responsible for ongoing liver injury. The strain of orally administered Salmonella Typhimurium that colonizes the liver would be engineered to secrete a particular protein or nanobody that would stop and / or reverse the progressive hepatic disease

Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and / or thymus weight loss in a mouse are disclosed as well as uses thereof. 20 24 27 84 77 16 D ec 2 02 4 A B S T R A C T 2 0 2 4 2 7 8 4 7 7 1 6 D e c 2 0 2 4

Providing expression constructs and their use. [Solution] This disclosure relates to isolated polynucleotides comprising sequences encoding the interleukin (IL)-12 molecule, and delivery systems capable of carrying the polynucleotides. This disclosure also includes methods for producing polynucleotides and methods for treatment using them. This specification provides isolated polynucleotides comprising nucleic acid molecules encoding the beta subunit of the IL-12 protein ("IL-12β"). This specification also provides isolated polynucleotides comprising nucleic acid molecules encoding the alpha subunit of the IL-12 protein ("IL-12α").

The present invention relates to Nav 1.7 and / or Nav 1.8 blocking hydroxamates. More specifically, the present invention is related to hydroxamates comprising the Formula (I), in which the substituents R1 to R10, as well as their derivatives R11 to R20, are selected independently of the groups defined in the specification, as well as their preparation processes, compositions comprising at least one of these compounds, uses, treatment methods to treat or prevent pain-related pathologies and kits. The present invention belongs to the fields of medicinal chemistry, organic synthesis, as well as the treatment of pain-related diseases.

The application is directed to compounds of formulae (IA) and (IB) and their salts and solvates, wherein R1a, R2a, R3a, A1, A2, A3, R1b, R2b, R3b, B1, and B2 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and / or prevention of, e.g., lysosomal storage diseases, such as Gaucher's disease, and α-synucleinopathies, such as Parkinson's disease.

This provides a novel treatment to improve patient outcomes for patients suffering from AP-4-HSP. [Solution] This disclosure relates to a transcription cassette comprising a nucleic acid molecule comprising a nucleotide sequence encoding an AP-4 subunit, a vector comprising the transcription cassette, a pharmaceutical composition comprising the vector, and a vector or composition for use in the treatment of AP-4-hereditary spastic paraplegia.

The present invention refers to Nav 1.7 and / or Nav 1.8 blocking hydrazides. More specifically, the present invention is related to hydrazides comprising Formula (I), in which the substituents R1 to R8 are selected independently of the groups defined in the specification, as well as their processes of obtaining, compositions comprising at least one of these compounds, uses, treatment methods to treat or prevent pain-related pathologies and kits. The present invention belongs to the fields of medicinal chemistry, organic synthesis, as well as in treatment of pain-related diseases.

Providing enriched antigen-specific antibodies for analytical and therapeutic use. [Solution] The present invention relates to a method for eliminating interference as described herein, or for enriching or isolating biomarkers, particularly antibodies, before diagnostic testing, or for use for prophylactic or therapeutic purposes, using particles (e.g., fine particles, nanoparticles; magnetic, nonmagnetic) having a surface containing the capture portion described herein. A simple, efficient, and cost-effective method for conditioning biological samples to control and mitigate a number of known sample-specific interferences that can result in erroneous test results and increased risks to patient safety, such as heterophilic antibodies in patients treated with monoclonal mouse antibodies or patients who have received them for diagnostic purposes, is described herein.

This disclosure relates to the use of cells having identifiable surface proteins, which have engineered or naturally occurring mutations but are functional surface proteins, for therapeutic use. The present invention also relates to the use of cells having identifiable CD33 surface protein variants but are functional surface proteins, for therapeutic use, particularly in adoptive cell therapy.

Described herein are oligonucleotides that are chemically stabilized and possess desirable properties for therapeutic use, and oligonucleotide polypeptide conjugates comprising the stabilized oligonucleotides for delivery and therapeutic uses.